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“Nog finns det mål och 
mening i vår färd, 
men det är vägen, som är 
mödan värd” 
 
”Yes, there is goal and 
meaning in our path – 
but it`s the way that is the  
labour`s worth” 
  
                        (Karin Boye) 
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ABSTRACT 
Background: Stroke is the 2nd most common cause of death after ischemic heart 
disease. About 85% of all strokes are caused by a thrombus or an embolus in the 
cerebral circulation. Stroke causes major handicap with impaired quality of life for 
the patients and their families and a large costs to society. Modern treatment of 
ischemic stroke includes thrombolytic and antithrombotic agents, but despite this 
treatment many patients do suffer a new ischemic stroke.  
 
Overall aim: To study hemostasis with emphasis on global hemostatic methods and 
try to identify subgroups of ischemic stroke with a more activated hemostasis, thus at 
risk of cerebrovascular complications.  
    
Paper I and II: 32 patients were recruited from the Stroke units at Danderyd 
Hospital and at Karolinska University Hospital. Blood samples was collected in the 
acute phase and in the convalescence of ischemic stroke. TAFI (an attenuator of 
fibrinolysis), Overall Hemostatic Potential (OHP; a global marker of hemostasis 
assessing both coagulation and fibrinolysis) and inflammatory markers were 
determined in plasma. We found an impaired fibrinolysis with increased levels of 
TAFI and a decreased fibrinolytic capacity assessed by the OHP-method (paper I). 
Furthermore, the fibrin network formed was found to be less permeable in ischemic 
stroke patients (n=20) as compared to controls, both in the acute phase and after two 
months. In addition, the network was more resistant to fibrinolysis (paper II) as 
measured by our global method of fibrinolysis.  
Paper III and IV: 209 patients with ischemic stroke (67%) or transient ischemic 
attack (TIA) (33%) were recruited from the Stroke units at Danderyd Hospital and at 
the Southern Hospital in Stockholm. Thrombin generation was measured by the 
Calibrated automated Thrombogram (CAT) and platelet activity was assessed by 
flowcytometric measurements of platelet-derived microparticles (PMPs) in plasma.  
Peak thrombin concentrations were found to be elevated both in the acute phase of the 
event and at one month (paper III). In addition, an increase in PMPs was present in 
the acute phase and at one month. They exposed tissue factor and P-selectin on their 
surfaces and these molecules may contribute to the activation of hemostasis in acute 
ischemic stroke (paper IV).  
 
Conclusion: Manifest ischemic stroke and TIA are conditions associated with an 
imbalance between coagulation and fibrinolysis, and elevated plasma levels of 
platelet-derived microparticles. Global methods of hemostasis may be useful in the 
evaluation of the hemostatic balance in ischemic stroke and a discrimination between 
high and low risk patients might be possible with standardized global assays in the 
future. 
 
Keywords: ischemic stroke, acute phase, fibrinolysis, inflammation, thrombin 
activatable fibrinolysis inhibitor, fibrin network permeability, fibrinogen, PAI-1, 
fibrinolysis profile, thrombin generation, endogenous thrombin potential, 
cardioembolic, transient ischemic attack, paroxysmal atrial fibrillation,                                      
microparticles, tissue factor, P-selectin, flowcytometry 
 
 
  2
LIST OF PUBLICATIONS 
I. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis 
and inflammation during the acute and convalescent phase of ischemic 
stroke.  
Rooth E, Wallen NH, Antovic A, von Arbin M, Kaponides G, Wahlgren N, 
Margareta Blombäck, Antovic JP. Blood Coagulation and Fibrinolysis 2007 
Jun 18 (4): 365-70. 
 
II. Decreased fibrin network permeability and impaired fibrinolysis in the acute 
and convalescent phase of ischemic stroke. 
Rooth E, Wallen NH, Blombäck M, He S. Thrombosis Research 2011 Jan; 
127(1): 51-6.  
 
III. Elevated thrombin generation in acute ischemic stroke and transient ischemic 
attack.  
Rooth E,  Sobocinski-Doliwa P,  Antovic J, Frykman V,  von Arbin M, 
Rosenqvist M, Wallén NH (Submitted). 
 
IV. Tissue factor and P-selectin expression on platelet-derived microparticles in 
patients with acute ischemic stroke or transient ischemic attack. 
Rooth E, Mobarrez F, Sobocinski-Doliwa P, Antovic J,  Frykman V, von 
Arbin M, Rosenqvist M,  Wallén NH (In manuscript form). 
 
 
Reprints were made with permission of the publishers. 
 
 
  3
CONTENTS 
1 INTRODUCTION ........................................................................................ 5 
2 BACKGROUND .......................................................................................... 7 
2.1 THE HEMOSTATIC SYSTEM ........................................................ 7 
2.2 THROMBOSIS AND STROKE ....................................................... 8 
2.2.1 History of stroke ..................................................................... 8 
2.2.2 Coagulation and stroke ........................................................... 8 
2.3 FIBRINOLYSIS AND STROKE .................................................... 11 
2.3.1 The properties of the clot / thrombus ................................... 11 
2.3.2 The fibrin network ................................................................ 11 
2.4 SUBTYPES OF ISCHEMIC STROKE .......................................... 13 
2.4.1 In research ............................................................................. 13 
2.4.2 In clinical practice ................................................................ 14 
2.4.3 Hemostatic disturbances in different subtypes of stroke ..... 15 
2.5 GLOBAL METHODS IN HEMOSTASIS ..................................... 17 
2.5.1 Historical perspective ........................................................... 17 
2.5.2 Screening assays of hemostasis ........................................... 18 
2.5.3 Global assays of hemostasis ................................................. 19 
3 AIMS .......................................................................................................... 22 
4 MATERIAL AND METHODS ................................................................. 23 
4.1 PATIENTS........................................................................................ 23 
4.2 METHODS ....................................................................................... 23 
4.2.1 TAFI ..................................................................................... 24 
4.2.2 OHP and OH index .............................................................. 25 
4.2.3 Fibrin network ...................................................................... 26 
4.2.4 CAT assay............................................................................. 27 
4.2.5 Microparticles ....................................................................... 28 
4.2.6 Other laboratory methods ..................................................... 29 
5 STATISTICAL ANALYSES .................................................................... 31 
6 RESULTS AND DISCUSSION ................................................................ 32 
6.1 PAPER I ............................................................................................ 32 
6.2 Paper II .............................................................................................. 32 
6.3 PAPER III ......................................................................................... 33 
6.4 PAPER IV ......................................................................................... 34 
7 GENERAL DISCUSSION ........................................................................ 36 
8 CONCLUSIONS ........................................................................................ 41 
9 FUTURE PERSPECTIVES ....................................................................... 43 
10 SVENSK SAMMANFATTNING ............................................................. 44 
11 Acknowledgements .................................................................................... 46 
12 References ................................................................................................... 49 
 
  4
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1 INTRODUCTION 
Stroke is the 2nd most common cause of death after ischemic heart disease 1. About 85% of all 
strokes are caused by thrombosis or thromboembolism of an artery in the brain. This 
condition causes major handicap with impaired quality of life for the patients and their 
families and to a large cost for society. With a growing aging population we will be 
challenged to prevent age-related diseases such as stroke. Modern treatment of acute brain 
infarction includes thrombolytic as well as antithrombotic treatment in order to dissolve the 
thrombus and prevent thrombus formation, respectively. However, despite secondary 
prophylaxis, as many as 30% of the patients will suffer a new ischemic stroke or a transient 
ischemic attack (TIA) 2. The annual risk of recurrence is about 4 %, with the highest risk 
during the 1st year (around 12%) and further research is needed in the area of biological 
markers and the possibility of their being targets of interventions in a clinical setting 3.  
   
 There are currently few opportunities to identify individuals who will suffer from a new 
ischemic stroke. It would be convenient to have biomarkers as guidance and inflammatory 
markers such as C-reactive protein (CRP high sensitive) have been associated with recurrent 
cardiovascular events 4, but measurements of such a marker has not yet been applied in routine 
stroke practice 3. In general, the stroke patients are treated in the same manner with the same 
antithrombotic agents with the same dosage regardless of ischemic subtype. One exception is 
cardioembolic stroke where oral anticoagulation has been shown to be the treatment of  
   choice 5 6 7. However, this type of stroke is commonly due to “silent” atrial fibrillation (AF), and 
thus identification and diagnosis may be difficult, and correct treatment may not be initiated 8. 
 
In about 40% of cases of ischemic strokes the pathogenesis is atherothrombotic 9. It is 
noteworthy that the old view of arterial thrombotic disease and venous thromboembolism (VTE) 
being two separate entities has been challenged as studies suggest they may share a common 
pathophysiology 10. VTE has been associated with an increased risk of cardiovascular disease 11 
and vice versa 12. The possible mechanisms and clinical implications of this phenomenon is yet 
to be explored but these intriguing findings definitely raises interest in the coagulation system as 
the target of research in an ischemic stroke population, as these patients share the same risk 
factors as patients with cardiovascular disease. 
 
   As for AF and stroke prevention, the use of risk scores, CHADS2 13 or the more recent 
CHA2DS2-VASC 14 to estimate the individual risk of ischemic stroke has reached a wide 
acceptance in the clinic. Unfortunately, these score-systems are restricted to patients with AF 
and not directed at the remaining part of patients who may also have a high risk for a recurrent 
ischemic stroke. As for TIA, a simple score system is available to assess early risk of stroke 
(ABCD2) 15 but for long-term risk assessments and for manifest ischemic strokes, better risk-
evaluation tools are demanded.  
 
   The risk of bleeding complications is the obvious drawback of anticoagulants and antiplatelet 
treatment. Even though a new user-friendly algorithm has been developed as an aid in the 
bleeding risk assessment of individual patients as regards to anticoagulation 16, the bleeding risk 
of those given antiplatelet agents are assessed mainly on the basis of clinical experience. Hence, 
limited means of evaluating a patient from different aspects opens up an avenue for new 
research within the area of hemostasis. One approach to evaluate “high-” and “low-risk” patients 
may be through laboratory tests with special focus on the hemostatic system 17. In the younger 
stroke population several coagulation factors have been associated with the ischemic stroke 
disease. Thus, when a hereditary or an acquired coagulation disorder is suspected an 
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investigation is usually performed with a directed assessment of single coagulation factors that 
could possibly alter the treatment strategy if they are significantly changed 18. However, this 
particular group of patients is in the minority as the mean age of ischemic stroke patients in the 
western world is well above seventy years of age. This excludes a large proportion of patients 
for whom one is “blind” to their individual “hemostatic risk pattern”.  
 
A tendency to treat elderly patients more cautiously with antithrombotic medication 19 is 
probably justified by the potential risk of bleeding complications. However, this might result in 
suboptimal medication for a patient with a very high recurrence rate of an ischemic stroke or 
TIA. Thus, we have a need for tools to allow us to judge whether the patient in front of us is at a 
high risk of a new event. One approach might be to evaluate patients through more global 
laboratory tests with special focus on the hemostatic balance 20.  
 
The main focus of the present work is on abnormalities of the blood constituents including the 
secondary hemostasis with fibrin network formation and lysis. Primary hemostasis is 
investigated by a study on microparticles from activated platelets. Below, a short introduction is 
given concerning the disturbances responsible for the formation of a thrombus. 
 
Fig 1. Virchow`s triad is applicable both in arterial and venous thrombosis. 
 
 
 
 
 
 
Modified from Favorolo, with permission from the publisher (Thromb Res, 2011, Suppl.2;13-16) . 
Virchow`s   triad 
Abnormal vessel wall 
Endothelial 
dysfunction/disturbances/damage 
Contact pathway activation 
Tissue factor release 
Abnormal blood flow 
(e.g. venous obstruction/stasis, 
atrial fibrillation, shear stress, 
post stenotic turbulence) 
Abnormal blood constituents 
Abnormalities in platelets/coagulation and 
fibrinolytic pathways 
Other cellular components / microparticles 
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2 BACKGROUND 
 
2.1 THE HEMOSTATIC SYSTEM 
Hemostasis (Greek hai`ma = blood, stasis = act or codition of stopping) is the physiological 
process by which the body is prevented from suffering an uncontrolled bleeding at a site of 
injury of a blood vessel, at the same time as the blood is kept flowing. Mechanisms are also 
there to prevent coagulation from progressing outside the injured site. When the vessel wall 
has healed underneath a thrombus, the thrombus will be dissolved by the fibrinolytic system 
and the vessel will resume its original function and shape. If, for some reason the thrombus is 
not resolved, it will eventually grow until it fills the whole lumen and blood flow will be 
obstructed. The area beyond the thrombus is starved of oxygen and will suffer from anoxia 
and cell death if blood flow is not restored. Thus, the balance between coagulation and 
fibrinolysis is very important and any condition that alters this balance is a potential threat to 
the equilibrium of hemostasis. In addition, hemostasis may also be partly involved in 
angiogenesis 21, which is of great importance in wound healing and vessel injury. With 
Virchow´s triad in mind (Fig 1), one of the three problems concerns abnormalities in blood 
constituents. A simplified flow chart of the hemostatic system is presented below (Fig 2) in 
which some processes of importance to the present thesis are emphasized.  
 
Fig.2. A schematic flow chart of the hemostatic system.  
 
 
                             
    
  
 
 
 
 
Bild Ringvor utan resultat! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular injury
Platelet activation Tissue factor 
Thrombin
Fibrin
Fibrin network
Fibrinolysis
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2.2 THROMBOSIS AND STROKE 
2.2.1 History of stroke 
Hippocrates was probably the first to acknowledge the stroke disease (400 B.C.) and he 
observed that persons suffering from apoplexy were mostly “between the ages of forty and 
sixty”. He noted that there were several blood vessels connected to the brain, and two of them 
were “stout”. It was common knowledge in Greece at that time that obstruction of these 
vessels could cause unconsciousness and therefore they were called the carotids, from the 
word Karos = deep sleep.  
 
It was not until the 17th century that the anatomic and clinical nature of the apoplexy was 
considered to be caused by an obstruction of either the carotids or the vertebrals, by two 
famous physicians, Wepfer (1620–1695) and Willis (1621–1675). Wepfer described the 
carotid siphon and the middle cerebral artery in connection with autopsy studies of patients 
who had died of apoplexy/stroke. Willis published “Cerebri anatomica” in which the 
anastomotic circle of the brain vessels was mapped and he also introduced the transient 
ischemic attacks. Rudolf Virchow (1821–1902), the famous German pathologist, was the first 
to describe the phenomenon of embolization, either in situ or as an artery-to-artery embolus in 
stroke and VTE;“The detachment of larger or smaller fragments from the end of the softening 
thrombus which are carried along by the current of blood and driven into remote vessels. This 
gives rise to the very frequent process on which I have bestowed the name of Embolia”.  After 
the Second World War the neurologist Fisher (born in 1913), observed that transient ischemic 
attacks (TIAs) frequently preceeded a manifest stroke and that TIAs were often caused by 
obstructions of the carotid arteries. In addition, he also made careful clinical observations and 
coupled them to pathological findings in the brain and thereby stated the five typical lacunar 
syndromes (pure motor, pure sensory, sensorimotor, ataxic hemiparesis and dysartria-clumsy 
hand syndrome) 22.  
 
2.2.2 Coagulation and stroke 
The general term for susceptibility to more easily coagulate the blood is called thrombophilia 
and includes both hereditary and acquired forms. There are several hereditary coagulopathies 
associated with cerebral thrombosis especially in younger stroke patients (< 45 years of age) 
and in children, although the associations found are consistently weak in the studies 
performed 23. Good anamnesis often raises the suspicion of a genetic or an acquired 
coagulation disorder. A variety of coagulation factors can be measured in plasma but it is not 
economically feasible or even wise to analyze all of them (Table 1).  
  
Table 1. Hereditary and acquired coagulation disorders associated with arterial thrombosis. 
(c=child, a=adult).  
  
Hereditary  Mixed  Aquired   
 
Protein S deficiency [c+a?] 24 25, 26 27   APS 
Protein C deficiency [c] 28-30   SLE   
Factor V Leiden [c+a?] 24 31         Hyperhomocysteinemia     Hyperhomocysteinemia 32 
Prothrombin G20210A [c+a] 31   
Antithrombin deficiency [c+a?] 33 34  
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2.2.2.1 Hereditary coagulation disorders 
Hereditary coagulation disorders are generally considered to be of greater importance in VTE 
than in arterial thrombotic conditions such as ischemic stroke. Below a short overview of the 
factors discussed in the literature is given: 
 
Protein S is a powerful inhibitor of the coagulation system as a cofactor to activated protein 
C (APC), and protein S deficiency has been reported in small case studies concerning adult 
ischemic stroke patients 25 26, of note, without control groups. However, in a recent 
prospective study no association between protein S-levels in plasma and stroke in middle-
aged men was shown 27.  
 
Protein C is a powerful inhibitor of the coagulation system and a deficiency of this factor has 
been shown to be associated with an increased risk of recurrent ischemic stroke in children in 
prospective studies 28. However, studies in adults have failed to prove the importance of 
protein C deficiency in cases of ischemic stroke 29, 30.  
 
Factor V is a cofactor of factor X (Fig 4, part 2.5.1) and a gene mutation which is called 
Factor V Leiden may cause APC-resistance. A weak relationship between the gene mutation 
and arterial thrombosis was present in a meta-analysis concerning adult stroke 31, but the 
heterogenous results in the studies made the conclusion doubtful 23. 
  
Prothrombin is the precursor of thrombin (Fig 4, part 2.5.1) and a specific mutation of 
prothrombin (G20210A) has been associated with a fairly strong stroke risk in prospective 
studies in adults 31 with an odds ratio (OR) of 1.44 (1.11–1.86). This provides some support to 
analyse this mutation in cases of  stroke in a young stroke person without any other apparent 
risk factor(s).  
 
Antithrombin (AT), the major inhibitor of thrombin (formerly called antithrombin III ) and a 
deficiency  is described in case reports concerning cerebral venous thrombosis 35 36, but case-
control studies have failed to reveal any associations between adult ischemic stroke patients 
and low levels of AT 34. In children with acute ischemic stroke, a recent meta-analysis of 
observational studies has established antithrombin as a contributing factor of thrombophilia 33.  
 
In conclusion, only a minority (approximately 1–4 %) of the younger ischemic stroke and TIA 
patients have a genetic coagulopathy that predisposes them to thrombosis 37. Thus, screening 
should be directed towards those stroke patients who have unexplained and recurrent 
thrombotic conditions at an early age and/or a strong family history. 
 
2.2.2.2 Acquired coagulation disorders 
More common than the inherited disorders are the aquired coagulation disorders (table 1) 
where the antiphospholipid syndrome (APS) is an especially intriguing syndrome. This 
syndrome is characterized by the presence of autoantibodies directed towards phospholipid-
protein complexes on cell-membranes. APS includes, in addition to the presence of 
autoantibodies, at least one episode of arterial thrombosis (stroke or MI) or venous 
thrombosis or an obstetric complication. The most common presentation of arterial 
thrombosis in APS is an ischemic stroke. Activated partial thromboplastin time (APTT) may 
be prolonged in APS and sometimes a mild to moderate increase of cardiolipin antibodies is 
found although its clinical relevance is uncertain. Full APS screening involving lupus 
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antibodies, cardiolipin antibodies and the more specific antiß2glycoprotein-1 antibody is 
therefore recommended, and this testing will identify patients at high risk of thrombosis 38.  
Autoantibodies should be demonstrable on two or more occasions, 12 weeks apart, preferably 
without anticoagulant treatment. Data are conflicting concerning the risk of stroke in APS. 
The results of prospective studies have proven an association 23 but the reliability of the data 
is uncertain because of difficult interpretation of the diagnostic methods 39. An overlap 
between APS and systemic lupus erythematousus (SLE) is present. The rare condition of 
(non-infectious) Libman-Sacks endocarditis found in SLE, with accumulation of immune 
complexes on the mitral valve is an uncommon source of cardioembolic stroke 40. APS and 
SLE occur more often in women than in men. 
  
Hyperhomocysteinemia Extremely high levels of homocystine in the urine were first 
described in 1962 to be associated with mental retardation, visual and skeletal problems as 
well as arterial and venous thrombosis at an early age. The plasma levels of homocystein in 
the children were more than 100 μmol/l as compared to the milder form (>15 μmol/l) that has 
been associated with a two-fold risk of ischemic stroke in cohort and case-control studies 32. 
The MTHFR (methylene tetrahydrofolat reductase) genotype has been found to be the cause 
of this disturbance in the folate metabolism 23 and since 2010 the screening test of all 
newborns in Sweden includes hyperhomocysteinemia. Milder forms can still be diagnosed in 
adults (www.socialstyrelsen.se/ovanliga diagnoser/homocystinuri).  
The mechanism(s) behind hyperhomocysteinemia and atherosclerosis progression is(are) not 
fully understood but may be through direct effects on the vascular endothelium, increased 
platelet adhesiveness and increased oxidation of LDL 41. Also direct effects on coagulation 
has been shown resulting in adverse effects 42 43. Therapeutic efforts involving B-vitamins 
have failed to reduce the risk of stroke in large randomized trials 44, 45.  
 
Other acquired coagulation disorders include polycytemia vera, systemic malignancy, 
myeloproliferative syndromes, thrombotic thrombocytopenic purpura (TTP), estrogen 
treatment, nephrotic syndrome and sickle cell anemia 9.  
 
2.2.2.3  Hemostasis and prognosis of ischemic stroke  
Beyond acquired thrombophilia per se, several hemostatic markers have been identified as 
prognostic factors of AIS: 
 
Fibrinogen is converted to fibrin by thrombin in the last step of the coagulation cascade (Fig 
4, part 2.5.1.), and the fibrin fibrils formed are cross-linked by factor XIII into an insoluble 
fibrin network. This plasma protein is also involved in platelet aggregation through binding to 
glycoprotein (GP) IIb/IIIa receptors. Fibrinogen is an important regulator of thrombin activity 
in clotting blood and, paradoxically, afibrinogenemic patients develop both arterial and 
venous thrombosis 46. Fibrinogen concentrations in plasma have most convincingly been 
shown to be independent riskfactors of ischemic stroke and coronary heart disease 47 – the 
higher the fibrinogen levels the greater the risk.  
 
Prothrombin fragment 1+2 (F1+2) is a prothrombotic marker and a 1:1 split product formed 
when prothrombin is converted to thrombin (Fig 4, part 2.5.1). Levels of F1+2 in plasma were 
independently associated with poor outcome after 3 months in ischemic stroke patients in the 
Heparin in Acute Embolic Stroke Trial (OR 1.77) 48. Also, in a study of 82 TIA patients, 
F1+2 plasma levels were found to predict a new cerebral or cardiovascular event when 
followed up for more than two years 49. Especially in the group of patients with multiple 
ischemic events (n=26), the mean F1+2 levels in plasma were significantly increased. 
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Furthermore, F1+2 has been shown to be persistently upregulated three months after an 
ischemic event 50, and in ischemic stroke patients with large aortic plaques and higher F1+2-
levels in plasma, a worse outcome was observed compared to those patients who had large 
aortic plaques but lower F1+2 levels 51. It was postulated that the increase of this marker of 
thrombin generation may reflect the atherosclerotic burden of the patient as endothelial 
damage and/or dysfunction can enhance activation of hemostasis.  
 
The thrombin-antithrombin complex (TAT), is another marker of thrombin generation and 
high plasma levels have been demonstrated both in cardiovascular disease 52 53, 54 and diabetes 
with complications 55. In ischemic stroke, an increase in TAT has been shown 56 but data are 
somewhat contradictory 50. Taken together, it seems that elevated thrombin generation is 
associated with more severe disease and poorer outcome in cases of ischemic stroke. 
 
In a prospective case-control cohort-study, VWF and the platelet secretory protein ß-
thromboglobulin were the hemostatic factors significantly predicting long-term mortality 
after ischemic stroke 57.  
  
   
2.3 FIBRINOLYSIS AND STROKE 
In addition to hereditary or aquired disturbances of coagulation, an impaired fibrinolysis may 
also contribute to the pathophysiology of ischemic stroke. As a short introduction, some 
additional aspects will be presented of thrombus formation and the characteristics of the 
thrombus: 
 
2.3.1 The properties of the clot / thrombus 
Fibrin-rich thrombi with entrapped red cells (red clots) are considered to be formed in a low-
flow system in contradistinction to platelet-rich (white) thrombi where the main constituents 
are platelets formed preferentially at high shear stress 58. According to the literature, the 
emboli in cardioembolic stroke are more commonly fibrin-rich and may be more readily lysed 
by intravenous thrombolysis with tissue plasminogen activator (tPA), as this fibrin-specific 
agent can persist within the thrombus for one or more days 59. Thus, one would expect a 
cerebral embolus e.g. from the heart is more prone to be lysed, but no such effect was seen in 
sub-group analyses of the NINDS trial 60. On the contrary, patients with rapid recovery has 
presented to a lesser extent with a cardioembolic source of stroke 61.  
 
However, the size and/or length of the thrombus are also important factors as endogenous 
lytic compounds like tPA and plasminogen or thrombolytic agents may not penetrate the 
thrombus as easily 62-64. Unfortunately, alternative treatments such as intra-arterial 
thrombolysis or mechanical thrombectomy by catheter intervention may also be more 
complicated to perform in such cases 65. 
 
2.3.2 The fibrin network 
The fibrin network structure of a clot may influence fibrinolysis. Thinner fibrin fibers are 
more easily lysed than thicker fibers. However, tighter fibrin networks are usually composed 
of thinner fibrin fibers packed closely together, resulting in smaller liquid pores between the 
fibers. This higher fiber density renders the network more difficult to lyse due to the fact that 
there are more fibrin fibers to be processed and there is restricted permeation of fibrinolytic 
factors into the tight network 66. The availability of fibrinogen - the “substrate” of the fibrin 
network - affects the structure of the fibrin network resulting in a tighter network in the 
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presence of higher fibrinogen concentrations 67, 68. Interestingly, a resistance to thrombolysis 
has been shown in a mouse model of experimentally induced hyperfibrinogenemia. This 
suggests causative connections between high fibrinogen levels, fibrin network formation and 
thrombotic complications 69.      
Potential ways through which elevated plasma levels of fibrinogen could lead to impaired 
dissolution of thrombi are shown below (Fig 3): 
 
Fig 3. Potential ways through which higher levels of fibrinogen can lead to thrombus 
formation and impaired dissolution of the thrombus 67. 
  
  
•   Platelet binding ↑ 
  •   Red blood cell binding ↑ 
  •   Fibrin network stiffness ↑ 
  •   Fibrin network pore size ↓ 
  •   Blood viscosity ↑ 
 
   
A tighter network has been observed in heart failure 70, coronary heart disease 71, diabetes 
mellitus 72, nephrotic syndrome 73, end-stage renal disease 74, rheumatic arthritis 75 and 
chronic obstructive pulmonary disease 76. In ischemic stroke patients, the fibrin network 
permeability has recently been demonstrated to be tighter in the acute phase and a relation to 
neurological deficit could be seen 77. However, larger prospective clinical studies on fibrin 
network structure and its relationship to future thrombotic complications are still lacking.     
 
2.3.2.1 Fibrinolysis in ischemic stroke disease 
Markers of the fibrinolytic system are of great interest in research on stroke, as in all other 
arterial thrombotic disorders. The most studied factor is plasminogen activator inhibitor-1 
(PAI-1). PAI-1 is the main endogenous inhibitor of tPA. The latter compound is important in 
fibrinolysis as it converts plasminogen to plasmin which in turn degrades fibrin.  
Elevation of plasma PAI-1 concentrations is present in various risk populations such as those 
with diabetes type 2 78, obesity 79, cardiovascular disease 80 and ischemic stroke 50. In addition, 
the 4G/5G polymorphism in the PAI-1-gene has been associated with ischemic stroke 81.  
 
D-dimer, a split product from the fibrin molecule, is usually considered to be a marker of 
“fibrin turnover” more than a marker of the fibrinolytic process itself. Levels of d-dimer in 
plasma have been shown to be elevated more than a month after an ischemic stroke 82 as a 
marker of an activated hemostasis.  
 
Thrombin activatable fibrinolysis inhibitor (TAFI), is a factor that attenuates fibrinolysis 
(for further information see Fig.8 part 4.2.1) and it is generated from circulating pro-enzyme 
of TAFI (pro-TAFI) by thrombin. In a study by Montaner et al. (2003) on 30 patients with 
ischemic stroke, TAFI antigen levels were found to be increased in the acute phase 83. 
Leebeek et al. (2005) demonstrated higher levels of functional TAFI in a 1:1 case-control 
study of more than 100 first-ischemic stroke patients at 7–14 days after the stroke 84. In 
prospective studies in cardiovascular disease patients, i.e. patients with similar risk profiles as 
ischemic stroke patients, high plasma levels of TAFI have been associated with increased 
cardiovascular mortality 85. In addition, in the ATTAC study, which involved a group of 
younger patients with first ever ischemic stroke and coronary heart disease, significantly 
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higher inactive TAFI levels were reported for patients compared with controls 86. In summary, 
TAFI seems to be an interesting factor in the context of arterial thrombotic conditions. 
 
2.3.2.2 Thrombolytic treatment and fibrinolytic markers  
Responders to thrombolytic treatment with tPA in acute ischemic stroke have been reported to 
have higher d-dimer peak-levels in plasma than the non-responders 87. Non-responders, in 
contrast, have been found to have higher PAI-1 concentrations in plasma at admission 88, 89. In 
a small study of patients undergoing thrombolytic treatment higher TAFImax levels were 
present in those who did not recanalise or who suffered neurological deterioration 90 although 
data are contradictory in this matter 89 91. The development of  TAFI inhibitors as 
profibrinolytic agents is promising 92 and as they are effective in animal thrombosis models 93, 
trials in patients are awaited. 
 
2.3.2.3 Platelets and ischemic stroke 
Hemostasis involves platelet activation which includes platelet adhesion, aggreggation and 
secretion of various biologically active factors e.g. ADP, ß-thromboglobulin, thromboxane 
and various coagulation factors which together promotes further platelet activation and 
thrombin generation. The platelets are considered to be mainly involved in arterial thrombosis 
especially under high shear stress. Platelets interacts and cross-talks with many other cells e.g. 
leukocytes and endothelial cells. The significance of platelets in ischemic stroke disease is 
undebated and antiplatelet agents are widely used as secondary prophylactic treatment, 
although their relative risk reduction is modest (only about 13%) 2.   
                            
 
2.4 SUBTYPES OF ISCHEMIC STROKE 
Ischemic stroke is a heterogeneous disease with various manifestations and plausible causes. 
The classifications available today take into account both the area of brain tissue damage and 
results of clinical investigations.    
 
2.4.1 In research 
2.4.1.1 TOAST/CCS 
The most widely used type of classification in research of stroke is the TOAST classification 
(Trial of Org. 10172 in Acute Stroke Treatment) system, originally created in a study of low- 
molecular-weight-heparin in acute ischemic stroke 94. The original study failed to show a 
favorable outcome 95, but the subtyping of stroke etiology was a useful contribution to the 
scientific community and the classification has since then been widely used in clinical studies 
in ischemic stroke.  
The subtypes included in the TOAST classification are large vessel disease, small vessel 
disease, cardioembolic stroke and other determined or undetermined/mixed cause.  
The major weakness of the TOAST classification is the fairly large proportion of patients 
classified as undetermined or mixed stroke etiology (commonly around 30 - 40%) even after 
extensive investigations. Yet another problem, though not specific to the TOAST 
classification, is the difficulty of detecting “silent atrial fibrillation”. This probably leads to 
underestimation of the prevalence of the cardioembolic stroke subtype. A further development 
into a computerized algorithm evaluation system, the TOAST-Causative Classification 
System (CCS) 96, has been performed to facilitate the classification procedure e.g. in large 
multicenter trials (CCS available at http://ccs.martinos.org).  
  14
Agreement between TOAST and CCS ranges from good to excellent 97 but investigator bias is 
present in all types classifications, reliability beeing higher as regards CCS than in TOAST 98.  
 
2.4.1.2 Bamford classification 
Bamford classification (also called the Oxford Community Stroke Project [OCSP] 
classification) of ischemic stroke is based on the patient`s neurological presentation assessed 
before any of the investigations into etiology have been performed eg. duplex imaging of the 
carotids or ECG. The syndromes are dependent on the affected ischemic area of the brain and 
are divided into Total Anterior Circulation Infarcts (TACI), Partial Anterior Circulation 
Infarcts (PACI), Posterior Circulation Infarcts (POCI) and Lacunar Circulation Infarcts 
(LACI) 99 (see Table 2 below): 
 
Table 2. Bamford classification. 
 
Area affected Total anterior 
circulation (TACI) 
Partial anterior 
circulation (PACI) 
Posterior 
circulation (POCI) 
Lacunar 
circulation (LACI) 
 
Signs 
 
All of: motor or 
sensory; higher 
cortical dysfunction 
eg. aphasia, neglect; 
hemianopia 
 
2 of the following: 
motor or sensory 
deficit; higher cortical 
dysfunction; 
hemianopia 
 
Isolated hemianopia; 
brain stem signs; 
cerebellar ataxia 
 
Motor or sensory 
deficit only 
 
This classification is excellent as regards to epidemiological research and research into 
pathophysiology, but in a clinical setting it is of limited use, as the treatment of ischemic 
stroke and TIA is the same (as yet) regardless of the area affected. It is sometimes hard to 
discriminate between small vessel disease in the posterior circulation and a “pure” posterior 
circulation syndrome. Occasionally, a patient´s symptoms do not allow clear classifiation, e.g. 
“tendency to fall to one side”, but that is often due to poor anamnesis and/or inadequate 
neurological examination. Investigator bias is high, and thus a reliability problem is present. 
Correlation with CT or MRI findings is poorly validated, although the correlation seems to be 
best in cases of anterior circulation syndrome and non-lacunar stroke 100.  
 
2.4.1.3  A-S-C-O 
The latest contribution to ischemic stroke etiological subtyping is the A-S-C-O-classification 
system published in 2009 101. This classification better takes into consideration the different 
levels of evidence (grades 1-3, 1 stands for high evidence) regarding A=atherosclerosis, 
S=small vessel, C=cardiac source and O=other causes of ischemic stroke (eg. A2S0C1O0). It 
may be good in very large epidemiological or in genetic studies, but due to the large number 
of possible categories this system is not suitable for studies with relatively small sample sizes.   
 
2.4.2 In clinical practice 
 
In clinical evaluation of a specific stroke patient it is most important to discriminate between 
cardioembolic and non-cardioembolic stroke, because efficient treatment with oral 
anticoagulants is available if an atrial fibrillation or an other high risk cardioembolic factor is 
found. Otherwise, an antiplatelet agent is considered sufficient as secondary prophylaxis. The 
risk of cardioembolic stroke in relation to clinical findings or heart disease is summarized in 
table 3. 
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Table 3. Type of heart disease and risk of cardioembolic stroke. 
  
High risk    Medium/low risk  
 
Atrial fibrillation/flutter   Calcification of mitral valve ring 
Acute myocardial infarction < 6 weeks  Patent foramen ovale 
Mechanical valve prosthesis   Atrial septum aneurysm and PFO 
Mitralis stenosis of rheumatic origin   Calcified aortic stenosis 
Atrial or ventricular thrombi   Bioprosthetic valve  
Atrial myxoma     Mitral valve prolapse 
Infectious/noninfectious endocarditis  Spontaneous echo contrast 
Complex aortic arch atheromatosis   Sick sinus syndrome 
Dilated cardiomyopathy 
Patent foramen ovale and systemic embolism  
 
Modified from TOAST-CSS classification and 102. 
 
 
2.4.3 Hemostatic disturbances in different subtypes of stroke  
 
Based on presumed pathophysiology, clinical manifestations and efficacy of different 
antithrombotic regimes, there is reason to believe that disturbances of the hemostatic system 
could be different in the different subtypes of ischemic stroke and TIA.  
 
2.4.3.1 Small-vessel disease   
Small-vessel disease (lacunar stroke) accounts for 20-25% of all cerebral infarcts 9 and is 
currently regarded as a matter of microscopic (lipohyaline) changes of the vessel wall with 
subsequent occlusion of the nutritional blood flow and a plausible “starvation” at the end 
artery area. In late stages of the “lacunar disease” a microthrombus is believed to be formed 
secondary to stagnation of blood flow 103. In cohorts of patients with small vessel stroke 
disease a reduced degree of hemostatic activation has been seen (Table 4), which fits with the 
presented pathophysiological model.  
 
2.4.3.2 Large-vessel disease 
Large-vessel (artery) disease accounts for about 5-10% of all cerebral infarcts and is mainly a 
result of a stenosis/atherosclerotic plaque in the internal carotid or vertebral arteries as a result 
of atherosclerosis. The ruptured arterial plaque, similar to that in myocardial infarction, and 
the turbulence of blood flow created over the stenosis leads to development of embolizing 
thrombi consisting mainly of platelet aggregates but also involving coagulation and fibrin 
formation. In severe cases the entire lumen of the carotid or vertebral artery is occluded and a 
large stroke will develop if the thrombus is not dissolved. Intracranial stenotic lesions are 
more common in Asians and Africans but very rare in Caucasians 104. Several studies have 
shown activation of hemostasis in patients with large-artery disease (Table 4).  
 
2.4.3.3 Cardioembolic stroke 
Cardioembolic strokes accounts for about 25% of all cerebral infarcts 102 and are most 
commonly due to embolization of a thrombus formed in the atrial appendage of the 
fibrillating left atrium. Emboli into the cerebral circulation follow the bloodstream and often 
end up in larger arteries (eg media circulation) where they occlude the vessel and generate 
strokes with more severe neurological deficits and subsequent worse prognoses 102. In 
cardioembolic stroke the suggested thrombotic mechanism is similar to that in venous 
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thromboembolism, and oral anticoagulating agents are effective in the prevention of future 
embolic stroke 105 106 107. In agreement with this idea, immunohistochemical studies have 
shown that the embolized thrombus is relatively rich in fibrin 108.  
Increased thrombin generation as measured by elevated plasma levels of the thrombin- 
antithrombin complex (TAT) and prothrombin fragments (F 1+2) have recently been found in 
patients after conversion of atrial fibrillation 109. A low d-dimer concentration in plasma in the 
acute phase has been suggested to make a cardioembolic stroke more unlikely. Thus, it has 
been postulated that this marker may be useful as a tool in the decisions regarding what 
clinical investigations should be performed 110. Cardioembolic stroke is regarded by many as 
the subtype with the most convincing evidence of hemostatic activation (Table 4).   
 
2.4.3.4 Undetermined stroke 
Undetermined (or cryptogenic) strokes accounts for about 30% of all cerebral infarcts and are 
often not presented in clinical studies of hemostasis, probably because of the heterogeneity of 
the patients and the lack of a clear-cut etiology. Nevertheless, this group is interesting because 
these patients can be regarded as possible “cardioembolic patients” (cryptogenic embolism), 
as a complete investigation can reveal e.g. a patent foramen ovale (PFO) or a paroxysmal 
(silent) atrial fibrillation 111. To our knowledge, only a few larger studies have concerned this 
group in the context of hemostatic evaluation (Table 4) if studies of hereditary coagulation 
disturbances are excluded ( part 2.2.2.1). 
 
Table 4. Hemostatic disturbances in different ischemic stroke subtypes.  
 
Subtype   Population      Main findings                   Year  
 
Small vessel  N=30*    d-dimer ↑, TAFI ↑                           2010 112      
                         PF4 ↑             
 N=38      F1+2  → d-dimer  →                    2001 113   
 
 N=58     FpA →, d-dimer →                       2000  56 
      Fibrinogen →,TAT → 
           ATIII →, FDP → 
                                  
 N=33                  PAI-1 ↑,  tPA ↑                               1996 114                                                   
  
                             N=12 (<7d )                               vWF →, PF4 →                             1993 82  
 N=15 (8-28d)                                       fVIIIC →, TF →                    
 N= 35 (>29d)                                       Fibrinogen → 
                       
  
Large vessel  N=170         F1+2 ↑                                         2008 51                                            
                                               
  N=10*         d-dimer ↑,TF ↑                             2003 115 
 
  N=41                                                       FpA ↑, d-dimer ↑                         2000 56  
                                                                  Fibrinogen  ↑, TAT ↑  
                                      ATIII →,FDP ↑ 
    
   N=10 (<7d)         d-dimer ↑                                      1993 82  
  N=9 (8-28d)      
  N=20 (>29d)  
 
Cardioembolic  N=26                   F1+2 ↑ Fibrinogen ↑                  2006 116  
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cont. Table 4. Hemostatic disturbances in different ischemic stroke subtypes.  
 
 
N=38 FpA ↑, d-dimer ↑                2000 56                                                            
Fibrinogen ↑,  TAT ↑ 
           ATIII ↓, FDP ↑ 
 
   N=23 (<7d   )                                          d-dimer ↑                                     1993  82  
                              N=17 (8-28d)                FPA ↑ ,TAT ↑             
                              N=20 (>29d)          protein C↓ 
                                 
   N=20                                  vWF ↑, fVIIIC ↑                           1990 117 
            Fibrinogen ↑, d-dimer ↑ 
             β-thromboglobulin ↑, PF4 ↑ 
 
  
  
Undetermined/       N=89           Ks ↓                                            2009 118                   
cryptogenic 
  N=162                 TAFI ↑                                 2007 119  
 
  N=56                              F1+2 →                                     2004 120         
 
*No other subgroup of ischemic stroke was included for comparison.  
Ks: fibrin network permeability coefficient, FpA: fibrinopeptide A, TAT: thrombin-antithrombin complex, 
FDP: fibrin degradation products, PF4: platelet factor 4. 
 
 
2.5 GLOBAL METHODS IN HEMOSTASIS 
 
From a clinical point of view, there is a desire to find a method which assesses a patient`s 
individual risk of recurrence of either stroke or myocardial infarction in a more functional 
way. Evaluation of more global functions of coagulation or fibrinolysis in the patient rather 
than measurement of single factors, would allow more confidence in the decision regarding 
prophylactic antithrombotic treatment. Here follows a brief overview of coagulation and 
fibrinolysis screening tests available:  
 
2.5.1 Historical perspective 
 
In 1964, two independent groups introduced a cascade or a “waterfall” model of coagulation 
composed of a series of steps in which activation of one clotting factor led to activation of 
another, finally leading to a burst of thrombin generation 121 122. This model was originally 
applied for laboratory purposes but was also widely spread as the reigning dogma of the 
coagulation system in vivo. The system is divided into  “extrinsic” and “intrinsic” pathways 
according to the type of activation (Fig 4): 
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Fig 4. The coagulation cascade with the traditional clotting assays: Prothrombin complex – 
International Normalized Ratio (PC-INR), activated partial thrombin time (APTT) and 
thrombin time (TT). 
 
     
Extrinsic     Intrinsic 
Vascular injury                     Contact activation 
activation                    XII 
                    prekallikrein 
      
                                                                                                                                       
     XIa       XI                
  
    
                 
     IXa     IX     
                        Tissue Factor             VIIIa 
            fVIIa    phosholipids 
---------------------------------------------------------------------------------------------------------------------  
         common pathway
                           
 
                        X               Xa   
                                                    Va    
                               phospholipids   
 
                         (prothrombin)  II             IIa (thrombin) 
 
 
    fibrinogen      fibrin 
 
Today a cell-based model is often used to describe the coagulation cascade. This model 
includes platelets, leukocytes and even red blood cells as important contributing components 
with which the coagulation co/factors interact 123.   
 
2.5.2 Screening assays of hemostasis                   
2.5.2.1 Prothrombin Time (PT) 
As a screening assay for the vascular injury (extrinsic) activation pathway group of 
coagulation factors we have the PT (or PC) measurement available in all clinical laboratories. 
This is used mainly for monitoring of vitamin-K-dependent anticoagulants such as warfarin. 
The assay was introduced in the 1930s by Quick et al. 124. The coagulation factors II, VII, IX 
and X are called the prothrombin complex (PC), and with the exception of factor IX, these are 
evaluated by the PT assay (Fig 4). The electromechanical change of the sample is measured 
by a sensor that monitors a ball rotating on the bottom of the cuvett. When the clot is created 
the ball is stopped and the clotting time is obtained (normally within 11–15 seconds). 
Nowadays many different methods of assessing PC-INR are used all over the world, but in 
Scandinavia we use a reagent consisting of TF-rich thromboplastins together with bovine 
plasma to start the coagulation process in the plasma sample 125. In an attempt to overcome 
the differences in the various reagents used in different laboratories around the world, the 
International Normalized Ratio (INR) is applied.  
 
2.5.2.2 Activated Partial Thrombin Time (APTT) 
Measurement of APTT (also known as Partial Thromboplastin Time, PTT) is a screening 
method for the contact activation (intrinsic) pathway and a majority of the coagulation factors 
are screened, except for factor VII (Fig 4). The method was developed in 1953 126 and 
estimates the time in seconds for clotting to occur in a plasma sample, i.e. time to detectable 
fibrin formation (normal range commonly 28–40 seconds). The reagents used today are 
PC-INR APTT
TT 
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calcium chloride, phospholipids (synthetic or from rabbit brain tissue) and a negatively 
charged contact activator (e.g. kaolin) as the triggers of clotting. The expression “partial” 
means that the reagent does not contain TF as in the PT assay and the result is always 
compared against a control plasma sample. In the antiphospholipid syndrome the APTT is 
paradoxically prolonged due to interaction with antibodies and phospholipids (lupus 
anticoagulans), even though the clinical consequence is venous or arterial thrombosis.  
 
2.5.2.3 Thrombin Time (TT) 
Measurement of TT, also called Thrombin Clotting Time (TCT), is a simple clotting test to 
evaluate the conversion of fibrinogen to fibrin by adding thrombin to citrated plasma. A 
slightly modified version of this method, i.e. diluted thrombin time, is considered to be useful 
to monitor treatment with the new direct thrombin inhibitors 127. TT is strongly dependent on 
the different reagents used, thus results between different labs can not be directly compared. 
The normal value of TT is usually around 15 seconds.  
 
2.5.3 Global assays of hemostasis 
As screening tests for bleeding disorders the clotting assays are excellent tools, but as for 
detection of hypercoagulable disorders they have been claimed not to be sensitive enough 20. 
Other methods to investigate hemostatic activation are therefore needed and new assays have 
emerged in the search for more global techniques in order to improve clinical descision-
making 128. Here follows an overview of the most common global assays of hemostasis:  
 
2.5.3.1 Thrombelastography (TEG)  
Thrombelastography was developed in 1948 by Hartert 129 and has many advantages as it is a 
bedside test in whole blood. Thus it can be used in critical situations such as sepsis, various 
types of surgery and following severe trauma. Using TEG, hemostasis under low shear stress 
conditions is monitored in the presence of all blood cells , thus allowing cell-cell interactions 
and cell-based coagulation. There is a mechanical detection system which allows us to 
visualize different typical graphical patterns giving information about the time until detectable 
fibrin formation, the kinetics of thrombus generation, the maximal amplitude (i.e. the strength 
and stability of the clot), and lysis time 130. Originally, no trigger of coagulation was applied 
in TEG except for calcium, but during recent years a modified version of the assay is often 
employed which uses minimal amounts of TF to trigger coagulation 131.   
  
New techniques have been developed where a rotating pin instead of a fixed piston (as in 
TEG) is used. Today the ROTEG® (Rotation Thrombelastography) 132 or ROTEM (Rotation 
Thrombelastometry) systems 133 are perhaps more widely used techniques than TEG. The 
major drawbacks of all these methods are the limited time between blood collection and 
analysis (samples must be analyzed within 8 hours), and the fact that frozen-thawed samples 
can not be used.  
 
2.5.3.2 Overall Hemostatic Potential (OHP) 
Measurement of OHP was developed by He et al. 134 and further modified 135 136 to be 
applicable in clinical bleeding and thrombotic conditions 20. By adding triggers of both 
coagulation and fibrinolysis, changes in turbidity are measured by spectrophotometry as fibrin 
is formed and lysed in the plasma sample. The OHP method was later further developed into 
the Overall Hemostasis Index assay (OH-index) 137 and these global methods have been used 
in the present work and are further described in the Methods section ( part 4.2.2.).  
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2.5.3.3 Other turbidimetric assays  
In the turbidimetric assay by Grant the clotting is triggered by the addition of small amounts 
of thrombin in combination with calcium 138 (similar to OHP). The method gives information 
about the functional aspects of fibrin formation, but not the more precise structure of the 
fibrin network. By measurements of absorbance (e.g. every 18 seconds for one hour) one 
evaluates how turbid the plasma gets when it clots and a graphical curve is plotted using a 
special software. Within the turbidimetric assay, the clot lysis is evaluated separately from the 
clot formation. This aspect of the assay is performed by adding tiny amounts of tPA before 
the addition of the coagulation trigger. Lysis is typically complete after one hour but readings 
may sometimes continue for up to nine hours depending on what plasmas that are investigated. 
The assay is quick and easy to performe, but it does not give the same precise information 
about the fibrin network properties as the fibrin network permeability assay does (see below). 
The CV is normally less than 10% 138 but as with all hemostatic methods it may be user 
dependent.  
 
2.5.3.4 Thrombin generation assays (TGAs) 
Interest in thrombin (factor IIa), responsible for the conversion of fibrinogen to fibrin, has 
resulted in various global assays in which thrombin generation is measured in a test tube with  
clotting triggers added. Thrombin generation assays have been used since the 1950`s to study 
coagulation in patients with hemorrhagic diseases or venous thromboembolism. At first TGAs 
were very time-consuming, but they were improved by Hemker et al. who replaced the 
manual work with automated continuous chromogenic measurements. Hemker also limited 
the assay to measure thrombin generation only, excluding the last stage, i.e the fibrin 
formation. This was done by removing fibrinogen from the plasma before analysis 139. 
Originally, a chromogenic substrate was used but nowadays a fluorogenic substrate is used in 
some assays instead of the chromogenic one. In the flourogenic method, thus, defibrination of 
plasma is unnecessary. The principle of the method is to measure the optical density, thus the 
appearance of thrombin generated in the plasma sample 140.  
 
The major part of thrombin is generated after the lag phase has terminated (i.e. after clotting 
time), thus only approximately 5% of total thrombin generated is measured with the 
traditional clotting assays APTT and PT 141. Thus, TGAs give additional information also on 
the kinetics of the total amount of thrombin generated in plasma. The coagulation process is 
initiated by different `triggers`, i.e. tissue factor, phospholipids together with calcium. The 
exact concentration of the triggers can influence the data 142 and there is some evidence of a 
better discrimination between “disease and health” using a lower TF-concentration 143. The 
Calibrated Automated Thrombogram (CAT), the Thrombin Generation Test (TGT) and 
Technothrombin TGA, are three commercially available TGAs 144. The CAT-assay is used in 
the present work and further explained in Methods section ( part 4.2.4.).  
 
2.5.3.5 Fibrin network assay 
Assessment of the last step of coagulation beyond thrombin generation, i.e. the formation of 
the fibrin network, can also be viewed upon as a global method. The fibrin network can be 
visualized in different ways e.g. through its morphology using light-scattering techniques 145, 
scanning electron 118 or confocal microscopy 146 (Fig 5). An evaluation of the functional 
properties of the fibrin network is feasible by way of a liquid permeability test 147 or by a gel 
turbidity assay. In this work the fibrin network permeability technique developed by 
Blombäck et al. has been used and is further described in Methods section ( part 4.2.3). 
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Fig 5. Fibrin network morphology. 
 
 
 
From Undas et al. with permission from publisher (Stroke, 2009; 40:1499-1501)      
  
 
 
Antovic et al. with permission from publisher (Thromb Res, 2005; 116:509-517) 
     
2.5.3.6 Clot lysis Time (CLT) 
The CLT assay is a global method of fibrinolysis in which triggers of both coagulation (TF 
and phospholipids and calcium) and fibrinolysis (tPA) are added to plasma and changes in 
absorbance are measured during clot formation and lysis. The coefficients of variation has 
been reported to be low (interassay 4%, intraassay 3%) 148. A typical CLT curve is shown 
below in Fig 6. 
 
Fig  6. Definition of Clot Lysis Time (CLT) estimated as the time from 50%-clear-to-max to 
50% max-to-clear turbidity.  
 
 
In this work we have used a slightly different CLT assay (performed as part of the OHP-
method) (Study I) but the principals are the same. This method has so far been used for 
research purposes only.   
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3 AIMS     
 
 
 
Overall aims:  
 
•  To investigate hemostasis in acute ischemic stroke (IS) through descriptive studies 
with emphasis on global methods 
 
•  Try to identify subgroups of acute IS patients with more activated hemostasis, thus being at 
potential risk of cerebral thromboembolic complications 
 
 
Specific aims: 
 
•  To study platelet-derived microparticles in acute IS 
 
•  To study thrombin generation in acute IS 
 
•  To study fibrin formation, fibrin network permeability and fibrinolytic capacity in acute IS 
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4 MATERIAL AND METHODS 
 
4.1 PATIENTS 
 
All patients included in this work were recruited from Stroke Units at three hospitals in 
Stockholm, i.e. Danderyd Hospital (n=177), Southern Hospital (n=95) and Karolinska 
University Hospital, Solna (n=9). The criteria for ischemic stroke were those according to the 
WHO 149, i.e. sudden onset of neurological deficit and/or signs of focal loss of cerebral 
functions with duration of more than 24 hours. A neuroradiological assessment, most often by 
computer tomography (CT) but on some occasions with additional MRI, excluded 
hemorrhagic stroke or other conditions such as tumors. The new definition of TIA was used, 
i.e. a transient episode of neurologic dysfunction caused by focal brain, spinal cord or retinal 
ischemia without evidence of acute infarction 150. Thus, neurologic events occuring for < 24 
hours with evidence of brain infarction were diagnosed as ischemic stroke, regardless of time 
of recovery. 
 
Fig 7. Distribution of participants in Studies I-IV. 
 
 
 
4.2 METHODS 
 
In Studies I and II the patients were recruited within 24 hours of symptom onset and a 
follow-up examination was performed at 60 days. In Studies III and IV the patients were 
recruited within two weeks of stroke onset and a follow-up examination was performed after 
approximately 30 days. Blood samples were taken in a fasting condition and after ten minutes 
of rest. The Stroke Units at Danderyd Hospital and at Södersjukhuset were responsible for 
sampling and were instructed to undertake atraumatic venous puncture without stasis. If stasis 
was necessary, a blood pressure cuff was used and a first extra “slush” tube was taken. At 
Karolinska Hospital a specially trained research nurse took the blood samples and delivered 
Participants 
Study I+II Study III+IV 
Study IV 
209 IS/ TIA 
65 controls 
Study I 
32 IS 
43 controls   
Healthy     
controls 
Study II 
20 IS  
23 controls 
Study III 
205 IS/TIA 
53 controls 
Participants 
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them to the lab. Blood samples were all handled in the same way with platelet poor plasma 
prepared from citrated (trisodium-citrate) whole blood (ratio 1+9) and K3-EDTA whole blood 
by immediate centrifugation (within 30 min) at room temperature at 2000 × g for 20 minutes. 
The plasma was thereafter aliquoted and frozen at -80°C until tested. Centrifugation and 
sample handling was performed at the Clinical Chemistry labs at the hospitals involved.  
 
4.2.1 TAFI 
 
In Study I we analyzed TAFI antigen concentrations by using a commercially available 
ELISA-method. TAFI is the short namne for thrombin activatable fibrinolysis inhibitor, also 
called Carboxypeptidase U. The TAFI molecule was discovered in the late 80`s by two 
independent research groups 151, 152 and defined further to be an attenuator of fibrinolysis 153. 
By its action as a carboxypeptidase it cleaves off the binding site for plasminogen to fibrin 
and thereby inhibits binding of plasminogen to the fibrin molecule. Thus less plasminogen 
will be bound to fibrin and less plasminogen will be converted to active plasmin by fibrin-
bound tPA (Fig 8). The target antibody used in the present study was directed towards the 
three different forms of TAFI antigens; pro-TAFI, active TAFI (TAFI) and inactive TAFI 
(TAFIi) and the method is described in more detail in Paper I. Thrombin (together with the 
cofactor thrombomodulin) is considered to be the most important physiological activator 92 
with conversion from pro-TAFI to TAFI (Fig 8). The nomenclature of TAFI can differ 
somewhat between studies. 
 
Fig 8. A. Degradation of fibrin by plasmin activated by tissue plasminogen activator (tPA). B. 
TAFI inhibits the activation of plasminogen to plasmin through cleavage of a carboxy-
terminal lysine residue (K) i.e. the binding site for plasminogen, from partially degraded 
fibrin.  
 
 
Modified from Bouma et al. with permission from publisher (Thrombosis Res, 2001;101:329-54). 
 
 
 
A. B. 
proTAFI         TAFI           TAFIi        +                  
thrombin 
thrombomodulin 
fibrin fibrin 
plasmin 
plasminogen tPA 
K K 
  25
 
4.2.2 OHP and OH index   
 
In Study I the Overall Hemostatic Potential (OHP) method was used as described by He et al.  
(2001) (see part 2.5.3.2.), a functional method to assess fibrin formation and lysis, performed 
in a 96-well microplate. The OHP curve is an absorbance curve formed and based on repeated 
spectrophotometric measurement after triggers of coagulation (calcium and thrombin) and 
fibrinolysis (tPA) have been added to the plasma sample in the well. The OHP curve is 
formed when both triggers of coagulation and fibrinolysis are present in the plasma sample . 
The Overall Coagulation Potential (OCP) is a curve formed when only triggers of coagulation 
are added. The Overall Fibrinolytic Potential (OFP) represents the difference between the 
areas under the OCP and OHP curves and is calculated according to the formula below: 
 
 
OFP = (OCP-OHP)  × 100% 
                                    OCP 
 
 
The OHP method is simple to perform. If a spectrophotometric reader is available (which  
usually is the case in a clinical chemistry laboratory) about 30 patient plasma samples can be 
analyzed within one hour. The calculations are carried out by using a simple Microsoft Excel 
software. OHP and OCP variables are expressed as Abs-sum (summation of absorbance) and 
OFP values are expressed as percentages. The method is described in more detail in Paper I.  
 
A further development of the OHP method, the Overall hemostatic index (OH index), was 
used in Stydy II 137. The principles are the same as in OHP, with triggers of coagulation and 
fibrinolysis added to the plasma sample, but the OH index assay takes into consideration both 
time and rate of coagulation and fibrinolysis (Fig. 9) in a more complex formula: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            h1            h2 
Coagulation profile (Cp) = (t1) -1   x   ---------             Fibrinolysis profile (Fp) =  t1   x   ---------     
               (t2   -   t1 )                                   (t4   -   t3 ) 
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Fig 9. The difference in optical density per time unit forms a curve from which the different 
variables of the OH index formula can be estimated. The formula stated above includes the 
different variables obtained from a curve of optical density changes per time unit.                                           
 
 
 
In this method low (picomolar) concentrations of tissue factor (TF) are used instead of 
thrombin in order to start “higher up” in the coagulation cascade and thus this method relies 
more on several different components present in patient plasma. Together with TF, washed 
frozen-thawed platelets and CaCl2 are added. Spectrophotometric data gathered in the same 
manner as in the OHP method. The raw data obtained are put into a software and the Cp and 
Fp are calculated (see formula above). The ratio of Cp to Fp is called the Overall hemostatic 
index (Oh-index) and is suggested to reflect the balance between coagulation and fibrinolysis 
in the plasma sample. 
 
4.2.3 Fibrin network  
 
The fibrin network assay was originally developed by Blombäck et al. 147 and further 
modified by He et al. 154. The method is based on the principle that fibrin formation in a 
plasma sample is triggered by addition of thrombin (or TF) and calcium. The fibrin network is 
left to mature into a gel in a plastic cylinder overnight. As can be seen below in Fig.11, buffer 
passes through the fibrin gel to evaluate its permeability. The volume of the eluate is collected 
under different hydrostatic pressures and the permeability constant (Ks) is calculated 
according to a formula (Fig 10) stated by Carr et al. 155. Information about the fibre 
mass/lenght ratio (μ) can also be provided. The major advantage of the modified assay is that 
it requires a considerably smaller plasma volume compared to the original method (250 μl 
instead of 3000 μl). In addition, the modified assay has been shown to have an even better 
reproducibility than the older version 156. The method is both labor- and time-consuming and 
approximately 8-10 samples can be analyzed in one day.  
 
 
 
 
 
 
▲OD/time unit 
60 min 
 t1 t2 t4 
h1 h2 
t3 
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format after calculation using a commercially available Thrombinoscope software®. The 
variables lag time, time to peak, peak height (i.e. peak thrombin concentration attained) and 
Endogenous Thrombin Potential (ETP; area under the curve), are obtained via the software 
(Fig 11).  
 
Fig 11. The Thrombogram curve of the CAT-assay.  
Blue = stroke patient. Red = healthy control. ttPeak = time to Peak. 
 
 
lagtime 
    
This method has acceptable reproducibility, with an interassay coefficient of variation of less 
than 5%. The CAT assay is convenient to perform and it takes only one hour for 32 samples 
to be run in a microplate.  
 
4.2.5 Microparticles 
 
Microparticles (MPs) are small vesicles “budding off” from apoptotic or activated cells such 
as platelets, endothelial cells and white and red blood cells. MPs have generally been 
considered to have procoagulant activity through the expression of negatively charged 
phospholipids (mainly phosphatidylserine; PS) (Fig 12). However, some studies suggest that 
MPs also may have a multitude of other biological effects, depending on the molecules they 
carry 157.  
 
Fig 12. A platelet-derived microparticle exposing various markers on its surface.   
 
Formation of MPs has been associated with various diseases such as multi-infarction 
dementia 158, multiple sclerosis 159 , antiphospholipid syndrome 160, 161, thrombotic 
thrombocytopenic purpura (TTP) 162, and ischemic stroke 158, 163 164. In diabetes type 2 165 and 
in acute coronary syndromes 166, conditions that often cooexist with stroke, MPs may also 
Peak height 
ttPeak 
Area Under the Curve = ETP
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play an important role. Platelet derived MPs (PMPs) are of interest in ischemic stroke both as 
markers of platelet activation and through possible biological effects e.g. procoagulant effects 
through expression of TF. As regards methodology, various assays have been used in previous 
stroke studies (Table 4). 
 
Table 4. Studies on platelet derived microparticles (PMPs) in ischemic stroke.  
 
Condition           Effect                      Number                     Method                Year 
                     of patients 
 
small vessel+               PMP (count) ↑                    52                       flowcyt                 1993 158 
large   ”         - small vessel ↑              (GPIb)                             
           than large v.   
 
 acute cerebral            PMP (Abs) ↑  252   ELISA                   2009 163 
 infarction            - large vessel  ↑   (CD42a/b  
            + “other inf” ↑       capture Ab)               
          ↓ at 1 month  
  
acute cerebral            PMP (Abs) ↑  110   ELISA                    2010 164 
infarction                           (GPIb human                
             capture Ab)    
 
Abs; absorbance. Ab; antibody. 
      
The opportunity arose to use a method developed in our laboratory 167 168 for analysis of 
PMPs. The method is described in more detail in Paper IV but in brief, this is a flow 
cytometric assay where the particles are gated according to size of the MPs (<1 μm). The flow 
cytometer is calibrated through the use of beads of different sizes. Fresh platelets are also 
used to check gating and settings. The cellular source of the MPs is determined through 
fluorescently labelled antibodies directed against cell-specific molecules may be used, such as 
CD41 or CD61 for platelets, CD144 for endothelial cells and CD45 for leukocytes. 
Phosphatidylserine (i.e. PS, mentioned above) can be measured by lactadherin binding 169 and 
varoius other markers exposed on  MPs can be measured as well (e.g. tissue factor or P-
selectin). This method makes it possible to assess platelet function in frozen plasma samples.  
 
4.2.6 Other laboratory methods 
Commercially available kits and calibrators were used to measure the standard inflammatory 
and hemostatic markers used in this study:  
 
4.2.6.1 CRP 
C-reactive protein (high-sensitivity assay) was determined using immunonephelometry (BN 
Systems; Dade Behring GmbH, Marburg, Germany). 
 
4.2.6.2 VWF 
For Von Willebrand factor antigen determination, the Liatest VWF (Diagnostica STAGO, 
Taverny, France) was used. 
 
4.2.6.3 Fibrinogen 
Fibrinogen was determined using immunonehelometry (BN Systems; Dade Behring GmbH, 
Marburg, Germany).  
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4.2.6.4 Prothrombin fragment 1+2 
Prothrombinfragment 1+2 (F1+2) was determined with an ELISA kit (Dade Behring) using a 
Multiscan MCC/340 (Flowlab, North Ryde, Australia).  
 
4.2.6.5 D-dimer 
Fibrin d-dimers were analyzed with latex fortified turbidometry (using a Sysmex CA-1500 
and reagents from Dade Behring.  
 
4.2.6.6 PAI-1 
Plasminogen activator inhibitor-1 antigen concentrations were analysed in plasma with an 
ELISA kit (Dade Behring) using a Multiscan MCC/340 (Flowlab, North Ryde, Australia).    
 
4.2.6.7 Routine analyses 
Concentrations of plasma lipids, plasma glucose, platelet counts and serum creatinine were all 
analysed by routine laboratory techniques at the Clinical chemistry laboratories at Danderyd 
Hospital, Södersjukhuset and Karolinska University Hospital, Solna, respectively. 
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5 STATISTICAL ANALYSES  
 
Here is an overview of the statistical analyses used in this work. For further details see Paper 
I–IV, respectively:  
 
• Students t-test – used between groups with normally distributed variables (Paper II).  
 
• Wilcoxon´s signed rank test and the Mann-Whitney U-test – used to determine if differences 
are present between groups of dependent or non-dependent skewed variables (Paper I-IV).   
 
• Spearman´s correlation coefficient – used to estimate if associations were present between 
continous variables, expressed as either r values or r2 values (Paper I-III). 
 
• The Kruskal Wallis test – a form of one-way ANOVA for non-parametric continuous 
variables, used for comparison between three or more groups. Dunn`s post hoc analysis is 
performed if the overall p-value is < 0.05 (Paper III, IV).  
 
• ANCOVA-analysis – a multivariat regression analysis of covariance between groups, and 
used to test for interactions of factors decided according to their possibility of influencing the 
dependent variable, e.g. age (Paper III).    
 
•  Mixed model analysis – used for compensation for samples lost by chance. A one-way 
repeated measures analysis of variance (ANOVA) using the procedure Mixed in SAS® 
(System 9.1) is performed. Skewed data is log-transformed preceding the analysis. (Paper I). 
  
 
For in-house statistical calculations Graph Pad Prism® 3.02 or Statistica Statsoft® were used. 
Values of p< 0.05 were considered statistically significant. 
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6 RESULTS AND DISCUSSION 
 
6.1 PAPER I 
Acute ischemic stroke – a hypofibrinolytic condition? 
 
The TAFI antigen concentrations in plasma were found to be elevated in the acute stage of IS 
but they were decreased 60 days after the event. Fibrinolysis, as measured by the global 
marker of fibrinolysis OFP, was also depressed and this hypofibrinolytic condition remained 
also at the 60 day measurement (Fig 13).   
 
Fig 13. Values of Overall Fibrinolytic Potential (OFP) in patients with ischemic stroke in the 
acute (day 0,1,3) and convalescent phase (day 60).  ** p<0.01, *** p<0.001 vs. controls. Data 
presented as mean ± 95% CI. No significant change over time including all four time points (one-way ANOVA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus, the main finding in this study was the observation of a decreased fibrinolytic capacity in 
IS. This was shown by way of two different methods, i.e. a global method of assessing overall 
coagulation and fibrinolytic capacity and through measurements of a single factor that 
attenuates fibrinolysis, i.e. TAFI. There were also relationships between inflammatory 
markers (CRP and fibrinogen) and fibrinolysis (OFP and to some extent TAFI), supporting 
the idea that hemostasis and inflammation interact in the pathophysiology of ischemic stroke.  
 
 
6.2 PAPER II 
Is a tighter fibrin network present in acute ischemic stroke? 
 
The fibrin network formed was found to be tighter in the acute phase of IS as compared to 
controls. Of note, this finding persisted after two months post-stroke despite enhanced 
treatment with antiplatelet drugs and statins (Fig 14), drugs known to make the fibrin network 
more porous 170 171 68. 
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Fig 14. Fibrin network permeability (Ks) in patients with ischemic stroke and in healthy 
controls. Patients were investigated in the acute phase (day 1) and after two months (day 60). 
Data presented as medians (boxes: 25-75th percentiles, bars: min-max). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This new finding was confirmed by another research group almost at the same time 172. 
However, our finding that the fibrin network was persistently tighter after the acute event was 
not reported in the study by Undas et al. Also, the additional information on decreased 
fibrinolytic capacity (decreased Fp) in the same population (Table 6) added an extra angle to 
our study as commented upon in a small editorial concerning our paper 17. Taken together, 
these findings were in line with the results in Study I, supporting the idea that ischemic stroke 
represents a hypofibrinolytic condition in which fibrinolysis has to “work against” a tighter 
fibrin network.  
 
Table 6. The Coagulation potential (Cp) and Fibrinolysis potential (Fp) in the acute (day 1) 
and convalescent (day 60) phases of ischemic stroke, and in controls. Data presented as median-
values (with 25-75% percentiles). Wilcoxon´s matched pairs test was used in intraindividual analysis. Mann-
Whitney U test was used in the comparison with controls. 
     
Patients day 1     Patients day 60     Controls 
        n=18          n=14           n=23 
  
Cp  3.4 (1.9 – 7.1)*  2.6 (1.8 – 4.1) ns 2.0 (1.1 – 3.2)  
Fp  0.9 (0.5 – 1.3)*** 0.9 (0.4 – 1.6)*** 2.3 (1.9 – 3.6) 
 
*** p<0.001  and * p<0.05, as compared with controls.  
 
 
6.3 PAPER III 
Is thrombin generation elevated in acute ischemic stroke? 
 
In Study III, we used a thrombin generation test (CAT) and observed a clear-cut increase in 
thrombin generation in a representative acute IS population (Fig 15). To our knowledge, this 
information has not been published before with this new kind of thrombin generation test in 
which the potential of the patient´s plasma to generate thrombin is evaluated (coagulation is 
started with the addition of TF). No difference in thrombin generation was observed in the 
various subtypes (TOAST, Bamford; data not shown), apart from the fact that a trend toward 
day 1 day 60 contr
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a higher thrombin generation seemed to be present in patients with a cardioembolic stroke due 
to a previously unknown paroxysmal atrial fibrillation (p=0.08) (Fig 2B, Paper III). 
 
Fig 15. Thrombin generation measured as peak thrombin concentrations during the acute 
phase of stroke and after 1 month, vs. healthy controls. *** p<0.0001, *p<0.05. Wilcoxon´s matched 
pairs test was used for intraindividual analyses.  Mann-Whitney U-test was used for comparisons between 
patients and controls. Data presented as median values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As can be seen in Fig 15 there was great inter-individual variability with respect to thrombin 
generation, with data from a bulk of patients lying well within the range of thrombin 
generation observed in healthy controls. It is clearly still too early to introduce this method in 
screening for hypercoagulability in stroke patients, even though use of the thrombogram is 
very easy and quick to perform. However, our study is of interest in the light of the results of 
a recent prospective study showing an increased risk of a future acute ischemic stroke 
(especially of the cardioembolic subtype) in patients with increased thrombin generation as 
measured by CAT 173.  
 
 
6.4 PAPER IV 
 
Are circulating PMPs elevated in acute ischemic stroke? 
  
The results in Study IV showed an increased number of circulating platelet-derived 
microparticles (PMPs) in IS, both acutely and after one month. This was in congruence with 
other studies in the field (Table 4, part 4.2.5). The particular novelty of our study was the 
marked elevation of PMPs that expose tissue factor and P-selectin (Fig 16), findings which 
are interpreted to reflect platelet activation. 
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Fig 16. Tissue factor positive (CD142) and P-selectin positive (CD62P) platelet derived 
microparticles (PMPs) in ischemic stroke and TIA patients in the acute (day 0) and subacute 
(day30) phase, vs. healthy controls. PMPs presented as absolute numbers. Data expressed as median 
(with 25-75th percentiles). (*** p<0.0001), Non-parametric Mann-Whitney U test and Wilcoxon´s signed rank 
test were used.  
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
A significant increase was present in all ischemic stroke subtypes (TOAST, Bamford; data not 
shown) regarding TF-expression. No significant differences in TF-expression were detected 
between the subtypes (TOAST and Bamford; data not shown).    
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7 GENERAL DISCUSSION 
As a clinician one is highly interested in the more functional aspects of the hemostasis, since 
such an understanding could make it possible to get an overall picture of the patients risk for 
thrombosis or bleeding. Thus, it would be convenient to be able to assess the balance between 
coagulation and fibrinolysis and from such data understand how to treat the patient in the best 
possible way. Measurements of single hemostatic factors involved in the process of 
coagulation or fibrinolysis may on the other hand be of great value in the understanding of 
pathophysiological mechanisms, but there is not always a good correlation between the levels 
of factors and the severity of symptoms present. Considering antithrombotic treatment there is 
also a great inter-individual variability in the response to antiplatelet therapy 174 and 
anticoagulants due to factors that can either be genetical 175 or due to differences in the inter-
individual hemostatic response.   
 
Stroke is a more heterogenous disease than the cardiovascular disease in terms of etiology 104 
and less is known about the more functional and global aspects of the hemostasis in the 
different subtypes of ischemic stroke than in cardiovascular disease 71, 176, 177. Also in diabetes 
patients, global methods of hemostasis have been used 72, 178, 179, but only a few studies have 
been performed in IS populations 180 181 and even fewer in acute IS. We could find no 
prospective studies with global hemostatic markers in the literature when this thesis was 
planned. Hopefully, this work have added some information about the pathophysiology of 
hemostasis in acute IS to enlighten what should be focused upon in future clinical and 
experimental studies. 
 
Hemostatic disturbances in acute ischemic stroke 
We found that hemostatic disturbances in patients with acute IS include an activated 
coagulation and in parallell an impaired fibrinolysis and a proneness to form a tighter fibrin 
network. In addition we observed signs of platelet activation as measured by elevated 
numbers of PMPs in plasma. These disturbances may be dependent on very different 
mechanisms such as endothelial dysfunction, inflammation and progression of atherosclerosis. 
Local factors like stasis with ensuing activation of coagulation may also contribute, especially 
if the patient suffers from atrial fibrillation.  
 
Microparticles 
We detected an increased numbers of platelet-derived microparticles (PMPs), and slightly less 
than 10% of  PMPs exposed TF (these PMPs also exposed phosphatidylserine). The presence 
of PMPs in plasma is interpreted to reflect platelet activation. Notably, PMPs may interact 
with coagulation through exposure of procoagulant phosphatidylserine and TF on their 
surface, both of which are measured in the flowcytometry assay used in the present thesis. 
There has been some controversies as to whether TF exposed on MPs (especially PMPs) is 
functional or not, and if it really has any impact on thrombogenicity 182 183 or is merely an 
“activation marker”. A recent study by Steppich et al. in patients with acute coronary artery 
disease reported, however, that circulating microparticles represent the major source of TF 
activity in plasma. It is therefore tempting to speculate that there may be a connection 
between our data on increased number of TF and phosphatidylserine postitive PMPs (study IV) 
and elevated thrombin generation (study III). However, correlation analyses did not support 
this idea. In addition, the CAT analysis performed uses addition of TF (in our study 5 pmol/l) 
and phospholipids at rather high concentrations and this makes it less likely that MPs present 
in the plasma sample have important influence on the thrombin generated in the test tube. 
Perhaps more likely is that the plasma composition, i.e. alterations in the concentrations of 
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various coagulation factors, influence thrombin generation and explains our findings as has 
been discussed in acute myocardial infarction 143. We have, however, no data available in our 
present study to support this assumption.  
 
MPs may also influence the fibrin network, as previously reported by our group 170 and others 
184. A tighter fibrin network would be expected if plasma contains a high number of MPs 
expressing phosphatidylserine and exposing TF, as this would enhance coagulation and 
thrombin generation. However, we did not adapt the fibrin network permeability assay to 
detect the possible effect of MPs as we added frozen-thawed platelets and TF to the plasma 
samples investigated. Thus, the tighter fibrin network formed in stroke patients as presented in 
study II, is unlikely to be due to elevated MPs and/or PMPs exposing TF.    
Further research investigating the potential “thrombogenicity” of the MPs in our stroke 
population is clearly needed. Experiments investigating the effect of these MPs can indeed be 
performed in the fibrin permeability assay as well as in the CAT analysis. 
 
Thrombin generation and fibrin formation  
We investigated two aspects of coagulation, i.e. thrombin generation and fibrin formation. 
Thrombin generation was investigated with the CAT assay (study III). The OHP-method 
(study I) and the OH-index method (study II) were used to study fibrin formation. Increased 
thrombin generation was observed in study III, and increased fibrin formation was observed 
in study I and II. The OHP method and the OH-index method differ however somewhat as 
regards the triggers of coagulation; in the OHP method thrombin was used and in the OH-
index method (study II), TF and frozed-thawed platelets were used. Thus slightly different 
approaches to evaluate fibrin formation were taken. However, both methods showed virtually 
the same thing, i.e. patients with ischemic stroke have an increased fibrin formation capacity. 
In addition, the CAT data indicate that this, at least in part, may be due to an increased 
thrombin generation. The global approach of the methods, i.e. their responses are dependent 
on several factors present in the plasma sample, makes it impossible to specifically determine 
the mechanisms. At present, the CAT analysis seems to be the most promising method of the 
global assays for coagulation used in this thesis if one is interested in prognostic studies, 
given the positive data recently published in the French case-cohort study mentioned 
previously (part 6.3) 173 and the interestingly wide variability in thrombin generation found in 
study III.  
 
Fibrin network 
The tighter fibrin network formed by stroke patients as compared to healthy controls is clearly 
a new and interesting finding. Mechanisms behind this observation are not known although 
plausible causes may include higher abundance of substrate (fibrinogen), increased thrombin 
generation and increased numbers of microparticles.  
 
The patients had higher plasma concentrations of fibrinogen which may influence the 
tightness of the fibrin network, but we observed a significant correlation between fibrin 
network permeability (Ks) and plasma fibrinogen concentrations only in healthy controls, but 
not in patients (study II). It is therefore likely that other factors also may be involved.  
 
One possible mechanism for the tighter network may be the increased thrombin generation   
observed in study III as it is well known that an increased thrombin generation leads to the 
formation of a tighter and more dense fibrin network. Another plausible cause of the obtained 
fibrin network data in study II is that there are higher numbers of MPs present in the sample. 
However this mechanism is not very likely, because the effects afforded by the frozed thawed 
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platelets and TF added, as mentioned above, probably overshadow the possible effects of MPs 
present in the plasma sample. 
 
Among the IS patients in study II there were also some subjects with diabetes (22%). As 
diabetes through glycosylation of the fibrinogen molecule may influence the fibrin network 
towards a more tight structure, it may be that such mechanisms also contribute to the 
differences observed between stroke patients and healthy controls. Indeed, higher glucose 
levels in the acute stage of stroke is a known factor of poor prognosis of stroke 185 and a 
recent study on more than 100 patients treated with i.v. thrombolysis found an eight-fold 
increase in poor outcome (measured by the modified Rankin scale) in patients of the upper 
tertile of insulin resistance 186. Whether this mechanistically involves the structure and 
composition of the fibrin network would be of great interest to elucidate in future studies.  
 
Fibrinolysis 
We assessed fibrinolysis through measurements of two endogenous fibrinolysis inhibitors (i.e. 
TAFI and PAI-1) and by employing three global methods, the overall fibrinolytic potential 
(OFP), the fibrinolysis profile (Fp) (these two assessments are included in the OHP and the 
OH-index assays, respectively), and the clot lysis time (CLT; study I). In addition, we also 
measured d-dimer in plasma.  
 
Our results all point towards the same direction - that ischemic stroke is a hypofibrinolytic 
condition. We found this to be the case both in the acute phase as well as in the convalescence 
of ischemic stroke. Thus, CLT was prolonged and OFP was reduced (study I) as was the 
fibrinolytic capacity (“fibrinolysis profile”; study II). Some correlations were also found 
between the single fibrinolytic markers and global fibrinolysis; TAFI correlated to CLT and 
was inversely related to OFP (study I). D-dimer levels were slightly but continuously elevated. 
This reflects ongoing fibrin formation and degradation (“fibrin turnover”), but is not a direct 
measurement of fibrinolysis. 
  
The mechanisms behind impaired fibrinolysis is likely to be at least in part connected to 
increased inflammation and in support of this idea we observed some relationships between 
inflammatory markers, and TAFI as well as OFP. It thus seems that ischemic stroke is 
characterized by an impaired fibrinolysis. No previous studies of the more global aspects of 
fibrinolysis in acute IS populations have been performed to confirme our results, but 
interestingly Anzej et al. found a decrease in OFP in a population of younger (< 45 years of 
age) IS patients (n=44) median five years after the event 181. This, together with a proneness 
to form a tight fibrin network as shown in study II, may indeed be of pathophysiogical 
importance with respect to thrombus formation and dissolution in IS. 
  
Ischemic stroke subtypes 
The small vessel (or lacunar) stroke did not differ from the other subtypes in any of the 
hemostatic markers measured in this thesis, in line with some studies 112, 114 but in 
contradiction to others 56, 113 82. This work does not support the idea of treating the small 
vessel group differently from an antithrombotic point of view. 
On the other hand, the cardioembolic subgroup due to AF seemed to have an elevated 
thrombin potential in line with reports from other research groups 56, 116, 117. They are therefore 
at increased risk of cerebral thromboembolic complications, justifying treatment with oral 
anticoagulants.  
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TIA versus stroke 
No significant differences in neither thrombin generation (measured by CAT) nor in 
microparticle activation could be detected between TIA and manifest IS patients. No study 
has, to our knowledge explicitly compared TIA and IS patients separately in studies of 
hemostasis. Lee et al.(Table 4, part 4.2.5) included the TIA group in the small vessel entity 158 
which is not quite true because a TIA can be seen in patients with a small and a large vessel or 
in a patient with a cardioembolic source.  
 
Objections may be raised against the fact that we have classified the TIA-patients with 
TOAST and Bamford in study III and IV, since these classifications have only been validated 
in populations with manifest stroke 94, 99. One argument justifying this way of action is that 
nowadays the border between TIA and manifest stroke is not as clear-cut due to the fact that 
approximately one-third of the TIA-patients present with an ischemic lesion on MRI 150. In 
addition, patients often have experienced both kinds of events in their medical history and 
TIA/stroke also share the same riskfactors and treatment strategies. Finally, a TIA-episode 
could be re-evaluated as a manifest stroke when the patient comes for a follow-up visit and 
tells about some of the neurological deficits experienced in connection with the “TIA-
episode” still to be present.  
 
In summary, the fact that we found no significant changes between TIA and manifest stroke 
in any of the hemostatic variables measured, supports the intention to have the same treatment 
strategies for TIA and ischemic stroke.     
  
How can these hemostatic disturbances be modulated? 
 
Life style aspects 
Hemostatic factors may be influenced by some changes in lifestyle. An increase in physical 
activity has been shown to have a positive effect on thrombin generation as measured by 
F1+2 in plasma 187 and obesity (both in adults 188 and in children 189)  is associated with 
elevated thrombin generation. Thus exercise and weight reduction would be assumed to 
reduce thrombin generation in patients with ischemic stroke, although obesity was not a large 
clinical problem in the stroke population investigated in this thesis. Smoking, another well-
known risk factor, affects both fibrin network tightness and clot lysis negatively 190. It is 
reasonable to assume that to stop smoking may beneficially influence these variables of which 
the fibrin network is, as shown in this thesis, adversely changed in patients with ischemic 
stroke. Only 6%, however, were smokers in study II, thus no statistical power could be 
reached.  
 
Treatment aspects 
The effect of low-dose aspirin has a positive effect on the fibrin network porosity by a 
postulated acetylation of lysine residues of the fibrinogen protein 191 68. It is conceivable that 
such an effect may be an additional mechanism explaining the beneficial effect of aspirin in 
IS and coronary artery disease. The Ks-values (reflecting network porosity) of the ischemic 
stroke patients studied in this thesis are almost in the same range as in diabetes patients 72 and 
in patients with coronary heart patients 176, although comparisons must be done with some 
caution as slightly different methods have been used. It should be noted, however, that low-
dose aspirin does not seem to be sufficient to reduce the tightness of the fibrin network found 
in this thesis. Thus, better treatment strategies are warranted. 
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Statins can be yet another way of attenuating the activated hemostasis in acute IS. As 
mentioned previously platelet microparticle expression of tissue factor and P-selectin are 
significantly reduced by statins 170, 171. This supports the use of statins in acute IS, and is in 
line with what has been shown in acute coronary syndromes 192. Also the fibrin network can 
become more porous following statin 170 and ACE-inhibitor treatment 193. Of note, treatment 
with ACE-inhibitors may also reduce thrombin generation 194 and this would strongly argue 
for increased use of ACE-inhibitors in stroke secondary profylaxis.  
 
Patients with paroxysmal atrial fibrillation had thrombin concentrations in the upper range. 
Prevention of AF through increased use of ACE-inhibitors and other drugs counteracting the 
renin-angiotensin-aldosteron system, may be yet another way to lower thrombin generation 194 
and decrease thromboembolic complications. Previous studies of anticoagulants in acute IS 
have been discouraged by the increased risk of bleeding complications 195, yet this would be 
perhaps the most powerful treatment to inhibit thrombin generation 196 improve fibrinolysis 
and make the fibrin network more porous 197. Notably, some evidence of beneficial effect of 
early anticoagulation has been presented in earlier studies, with a significantly reduced risk of 
having a recurrent stroke within the first two weeks 195. This supports indirectly the results of 
this thesis of an activated hemostasis as a part of the acute IS pathophysiology and suggest its 
reversal by a early direct anticoagulating treatment.  
 
General remarks 
In summary, the hemostatic disturbances of acute ischemic stroke patients involves, as shown 
in this thesis, indeed all three “corners” of Virchow`s triad (Fig 1). These disturbances may in 
part be due to atherosclerosis as the site of vascular injury and a potential “starting point” for 
the hemostatic activation (Fig 2 and 17). A causality between the hemostatic system and 
progression of atherosclerosis has recently been proposed by the research group of Ten Cate 
198. Disturbances of hemostasis may also partly be a consequence of the stroke itself, with an 
acute phase reaction which declines in due course.  
Regardless of etiology, global assays of hemostasis would provide a possibility to assess the 
hemostatic balance in ischemic stroke patients, used as a complement to conventional risk 
factor evaluation. There is, however no global assays ready to be introduced into the clinical 
point-of-care situation. At present, the Calibrated automated thrombogram is probably the 
strongest candidate of the methods used in this thesis.  
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8 CONCLUSIONS 
 
Fig 17. A schematic flow chart of the hemostatic system and thesis results.   
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OVERALL CONCLUSIONS  
 
      •  A disturbed hemostasis is present in patients with ischemic stroke (IS), both during the 
acute and convalescent phase of the disease. Disturbances involve platelet function, 
thrombin generation, fibrin formation and the structure of the fibrin network, as well as 
fibrinolysis.  
  
       •  No differences in the pattern of disturbances of hemostasis could be seen when 
different subtypes of IS were compared, except for a tendency towards an increased 
thrombin generation in cardioembolic stroke due to paroxysmal atrial fibrillation.  
 
       •  Large prospective studies should be carried out to determine the potential value of 
global methods evaluating the balance between coagulation and fibrinolysis in plasma 
from patients with IS. Until then, the global hemostatic methods tested in the present 
thesis are not ready to support the decision-making concerning antithrombotic treatment 
strategies.  
       
 
SPECIFIC CONCLUSIONS  
  
    •   Platelet-derived microparticles in plasma are significantly increased in IS, both during 
the acute and in the subacute phase of the disease. This reflects increased platelet 
activation. 
 
    •   The number of platelet-derived microparticles in IS patients that expose tissue factor and 
P-selectin on their surface are greatly increased. 
 
   •   No differences could be detected between subtypes of IS regarding the exposure of 
tissue factor or P-selectin on platelet-derived microparticles. 
 
     •   An increased thrombin generation measured by CAT is present in plasma from patients 
with IS, both in the acute phase and after one month. 
 
  •   The cardioembolic subgroup had a trend towards a more prominent thrombin generation    
measured by CAT as compared to the non-cardioembolic group. 
 
    •   Plasma from IS patients is characterized by its ability to form a less permeable fibrin 
network. This ability is present in the acute phase and seems also to be present two 
months post-stroke. 
 
   •   IS is associated with increased TAFI and PAI-1 antigen levels in plasma, and a  
decreased fibrinolysis as measured by two global fibrinolysis methods. 
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9 FUTURE PERSPECTIVES 
It is rather difficult to tell whether the tighter fibrin network is a phenomena caused by the 
stroke itself or if it is a phenotype present even before the stroke occur. We did not design the 
study in such a fashion, but of course it would be interesting to follow a group of stroke-free 
subjects for a longer period and measure the fibrin network at baseline. A population with 
atrial fibrillation without a TIA/stroke in the history is a tempting target for a new study. 
Unfortunately, until a more automized method is available, this would turn the laboratory staff 
crazy as this would become a very time- and labourconsuming study.  
 
More than four years have passed since the first patient in study III and IV was included 
(2007 20th of June) and we now have a golden opportunity of a follow up study to evaluate 
both microparticles and CAT-data in a prospective manner. 
 
Lifestyle interventions are interesting in the context of hemostasis and a fairly large 
randomised study in patients with impaired glucose tolerance or diabetes and ischemic stroke 
would be of great interest with evaluation using some of the methods presented in this thesis.   
 
Finally, if we could be able to agree upon the best global assay of hemostasis and get it 
standardized with a low inter/intra-assay variability, one hopes for a tool in the future with 
which we can foresee the individual risk for new cardiovascular events. In that way one can 
be able to tailor the treatment and know when to initiate or abstain from antithrombotic 
treatment. 
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10 SVENSK SAMMANFATTNING 
Stroke är den andra vanligaste orsaken till dödlighet efter hjärtkärlsjukdom. Cirka 85% av alla 
strokefall är orsakade av en hjärninfarkt (blodpropp i hjärnans cirkulation). Modern 
behandling av akut hjärninfarkt innefattar trombolys (blodproppsupplösande behandling) och 
blodförtunnande behandling för att förhindra nya proppbildningar. Trots denna behandling är 
det många patienter som drabbas av en ny stroke. 
 
I kroppen finns ett system som gör att blodet sig hela tiden håller flytande i blodkärlen och 
som kallas för hemostasen. Detta är en finstämd balans mellan å ena sidan benägenheten att 
bilda blodproppar (koagulationen) och å andra sidan förmågan att lösa upp bildade proppar 
(fibrinolysen). Om denna balans blir störd av någon anledning kan blödningar eller 
blodproppar uppstå lättare. I denna studie undersöktes patienter med hjärninfarkt eller TIA 
(övergående syrebrist till hjärnan) där vi med tyngdpunkt på olika globala metoder som mäter 
balansen i hemostasen, ville se vilka som hade den största störningen i hemostasen och 
därmed sannolikt löper störst risk för nya stroke.  
  
I den första pilotstudien på 32 patienter med akut hjärninfarkt (Studie I) mättes en faktor som 
dämpar fibrinolysen, den s.k. trombin aktiverade fibrinolys hämmaren (TAFI) i blodprov. 
Parallellt undersöktes också balansen i hemostasen med en global metod, Overall Hemostatic 
Potential (OHP). Resultaten visade att TAFI var förhöjt i akuta skedet efter stroken men att 
värdena hade normaliserats efter två månader. Den fibrinolytiska förmågan, d.v.s. förmågan 
att lösa upp proppar, visade sig vara nedsatt både akuta och efter 2 månader.  
I nästa studie (Studie II) på samma grupp av patienter, analyserades genomsläppligheten hos 
det fibrinnätverk som ”armerar” blodproppen när blodet koagulerar. Fibrinnätverket bildat 
under standardiserade former utifrån plasma från patienter med akut hjärninfarkt, visade sig 
vara tätare än hos motsvarande friska personer. Återigen kunde vi se att den fibrinolytiska 
förmågan var nedsatt både i akuta skedet och efter 1 månad, denna gång med en 
vidareutvecklad metod, Overall hemostatic-index (OH-index). 
 
I en betydligt större studie med mer än 200 patienter med akut hjärninfarkt och TIA, utfördes 
riktade undersökningar för att hitta dolda förmaksflimmer. För att försöka hitta undergrupper 
av strokepatienter med ökad aktivitet i koagulationssystemet, gjordes en analys i blodet med 
en metod som mäter bildningen av trombin (det protein som deltar i det sista steget i 
koagulationen för att bilda fibrin), Calibrated automated thrombogram (CAT) (Studie III). 
Där såg man att patienterna hade en ökad trombinbildning jämfört med motsvarande friska 
kontroller, med en trend mot ökad bildning hos de patienter som befanns ha ett övergående 
förmaksflimmer. I den sista studien (Studie IV) mättes antalet mikropartiklar (som är kända 
för att aktivera koagulations-faktorerna) i blodet. Antalet mikropartiklar visade sig ligga 
signifikant högre hos patienter med akut hjärninfarkt och TIA.  
 
Sammanfattningsvis är akut hjärninfarkt och TIA förenat med en störd balans med å ena sidan 
en ökad koagulation och å andra sidan en försämrad fibrinolys. Hur kan man då sträva efter 
att återställa balansen mellan koagulationen och fibrinolysen hos stroke patienterna? Med de 
effektiva blodförtunnande och blodfettsänkande läkemedel vi har idag kan hemostasen 
påverkas positivt och därför är det viktigt att diagnostisera och behandla hjärninfarkt och TIA 
så snabbt som möjligt. Förbättrad livstil kan sannolikt också påverka en del av de 
hemostasförändringar som uppdagats inom ramen för denna studie. Framtida studier får 
avgöra om riktade livstilsråd kan förbättra balansen mellan koagulation och fibrinolys hos 
stroke patienter. Den patient-nära vården är inte redo för beslut gällande ändringar av 
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behandling val av blodförtunnande behandling grundat på de metoder som används i denna 
avhandling, studier som följer patienterna över en längre tid behövs först.   
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